1. Home
  2. CVM

as of 02-02-2026 3:55pm EST

$5.29
$0.43
-7.60%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Founded: 1983 Country:
United States
United States
Employees: N/A City: VIENNA
Market Cap: 43.3M IPO Year: 1987
Target Price: N/A AVG Volume (30 days): 80.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -6.27 EPS Growth: N/A
52 Week Low/High: $1.98 - $20.41 Next Earning Date: 02-13-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered CVM Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 74.84%
74.84%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Cel-Sci Corporation (CVM)

KERSTEN GEERT R

Chief Executive Officer

Buy
CVM Jan 22, 2026

Avg Cost/Share

$5.26

Shares

38,023

Total Value

$200,000.98

Owned After

120,815

SEC Form 4

KERSTEN GEERT R

Chief Executive Officer

Buy
CVM Dec 4, 2025

Avg Cost/Share

$5.96

Shares

8,389

Total Value

$49,998.44

Owned After

120,815

SEC Form 4

Share on Social Networks: